Han Y.

Dr. Ying has over 20-year experience in immunology, the pharmaceutical industry, biotech start-ups, operation, clinical study, and biotech investment. He received his PhD at Stanford University in Cancer Biology and immunology, completed his postdoctoral training in immunotherapy with Drs. Nicholas Restifo and Steven Rosenberg at the US National Cancer Institute. He was one of the first scientists in the world to develop self-amplifying RNA and DNA vaccines, and he published 6 important scientific articles on RNA and DNA vaccines from 1998 to 2002, including two in Nature Medicine. He became a principal investigator at MDNI (affiliated with UCLA), where he oversaw a clinical laboratory conducting Dendritic Cell Vaccine trials for malignant brain tumor. He joined Berlex Biosciences (the R&D arm of Schering A.G.) as a project manager in the cancer research department, then joined Monogram Biosciences, a personalized medicine company that developed biomarker assays for selection of patients for novel targeted drugs. In 2010, Dr. Ying co-founded Immunnova, a biotech company focused on dendritic cell vaccines and antigen-specific T cells. He has served as senior members for several early or late-stage biotech companies in immunotherapy, including HRYZ (DC-based Cell Therapy), Sanpower Group/Dendreon in China and the US. He was the key technical expert in an international M&A team that completed the acquisition of Dendreon by Sanpower group (0.9 billion dollars), and acquisition of China Life Science in Hong Kong. He helped build the Dendreon China team and a state-of-the-art GMP cell factory in Shanghai. He was a founding team member of T-Cure Bioscience in Los Angeles and helped successfully raise A and A+ round (22 million dollars). He is currently CTO of Base Therapeutics which owns the best form of prime-editing/base editing technologies. He is a venture partner of Panacea Venture.